CAR T-Cell Therapy Market

CAR T-Cell Therapy Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

180

Base Year:

2022

Nov - 2023

Format:

Report Code:

VMR-2336

Segments Covered

By Drug Type Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types
By Indication Lymphoma, Acute Lymphocytic Leukemia, Other Indications
By End User Hospitals, Cancer Treatment Centers
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 2 Billion
Revenue 2030:	USD 5.9 Billion
Revenue CAGR (2023 - 2030):	14.6%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Global CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. Global CAR T-Cell Therapy Market - by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. Global CAR T-Cell Therapy Market - by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. Global CAR T-Cell Therapy Market - by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. Global CAR T-Cell Therapy Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
7. Market comparative analysis
North America CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. North America CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. North America CAR T-Cell Therapy Market, by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. North America CAR T-Cell Therapy Market, by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. North America CAR T-Cell Therapy Market, by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. North America CAR T-Cell Therapy Market, by Country
  1. U.S.
    1. U.S. CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. U.S. CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. U.S. CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  2. Canada
    1. Canada CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Canada CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Canada CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  3. Mexico
    1. Mexico CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Mexico CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Mexico CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
Europe CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Europe CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. Europe CAR T-Cell Therapy Market, by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. Europe CAR T-Cell Therapy Market, by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. Europe CAR T-Cell Therapy Market, by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. Europe CAR T-Cell Therapy Market, by Country
  1. Germany
    1. Germany CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Germany CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Germany CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  2. UK
    1. UK Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. UK Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. UK Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  3. France
    1. France CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. France CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. France CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  4. Spain
    1. Spain CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Spain CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Spain CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  5. Italy
    1. Italy CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Italy CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Italy CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  6. BENELUX
    1. BENELUX CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. BENELUX CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. BENELUX CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  7. Rest of Europe
    1. Rest Of Europe CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Rest Of Europe CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Rest Of Europe CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
Asia Pacific CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. Asia Pacific CAR T-Cell Therapy Market, by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. Asia Pacific CAR T-Cell Therapy Market, by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. Asia Pacific CAR T-Cell Therapy Market, by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. Asia Pacific CAR T-Cell Therapy Market, by Country
  1. China
    1. China CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. China CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. China CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  2. Japan
    1. Japan CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Japan CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Japan CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  3. India
    1. India CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. India CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. India CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  4. South Korea
    1. South Korea CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. South Korea CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. South Korea CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  5. South East Asia
    1. South East Asia CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. South East Asia CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. South East Asia CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Rest of Asia Pacific CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Rest of Asia Pacific CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
Latin America CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Latin America CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. Latin America CAR T-Cell Therapy Market, by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. Latin America CAR T-Cell Therapy Market, by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. Latin America CAR T-Cell Therapy Market, by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. Latin America CAR T-Cell Therapy Market, by Country
  1. Brazil
    1. Brazil CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Brazil CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Brazil CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  2. Argentina
    1. Argentina CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Argentina CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Argentina CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  3. Rest of Latin America
    1. Rest of Latin America CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Rest of Latin America CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Rest of Latin America CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
Middle East & Africa CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
3. Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
  1. By Axicabtagene Ciloleucel
  2. By Tisagenlecleucel
  3. By Brexucabtagene Autoleucel
  4. By Other Drug Types
4. Middle East & Africa CAR T-Cell Therapy Market, by Indication
  1. By Lymphoma
  2. By Acute Lymphocytic Leukemia
  3. By Other Indications
5. Middle East & Africa CAR T-Cell Therapy Market, by End User
  1. By Hospitals
  2. By Cancer Treatment Centers
6. Middle East & Africa CAR T-Cell Therapy Market, by Country
  1. GCC Countries
    1. GCC Countries CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. GCC Countries CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. GCC Countries CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  2. South Africa
    1. South Africa CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. South Africa CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. South Africa CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa CAR T-Cell Therapy Market, By Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    2. Rest of Middle East & Africa CAR T-Cell Therapy Market, By Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    3. Rest of Middle East & Africa CAR T-Cell Therapy Market, By End User
      1. By Hospitals
      2. By Cancer Treatment Centers
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Celgene Corporation (U.S.)
2. Cartesian Therapeutics Inc. (U.S.)
3. Miltenyi Biotech (Germany)
4. Autolus Therapeutics (UK)
5. Caribou Biosciences Inc. (U.S.)
6. Gilead Sciences Inc. (U.S.)
7. Merck & Co. Inc. (U.S.)
8. Intellia Therapeutics (U.S.)
9. Juno Therapeutics Inc. (U.S.)
10. Bristol-Myers Squibb (U.S.)
11. Novartis AG (Switzerland)
12. Bluebird Bio Inc. (U.S.)
13. Sorrento Therapeutics Inc. (U.S.)
14. Pfizer Inc. (U.S.)
15. Cellectis (France)
16. Celyad Oncology (Belgium)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 22-Nov-2023

CAR T-Cell Therapy Market to Reach Valuation of USD 5.9 Billion by 2030 – Surge in Demand for Effective Cancer Treatments and Favourable Reimbursement Policies in Certain Countries Drives the Market

FAQ

Frequently Asked Question

What is the global demand for CAR T-Cell Therapy in terms of revenue?

The global CAR T-Cell Therapy valued at USD 2 Billion in 2022 and is expected to reach USD 5.9 Billion in 2030 growing at a CAGR of 14.6%.

Which are the prominent players in the market?

The prominent players in the market are Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 14.6% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the CAR T-Cell Therapy include
- Surge in prevalence of cancer

Which region accounted for the largest share in the market?

North America was the leading regional segment of the CAR T-Cell Therapy in 2022.

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for CAR T-Cell Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for CAR T-Cell Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for CAR T-Cell Therapy Market

Vantage Point Interactive Dashboard